- Home
- CSR vs SVRA Comparison
CSR vs SVRA Comparison
Compare CSR & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSR | SVRA |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | United States |
| Employees | 349 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.8M | 1.1B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | CSR | SVRA |
|---|---|---|
| Price | $61.04 | $5.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $69.80 | $7.33 |
| AVG Volume (30 Days) | 100.8K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.24 | N/A |
| Revenue Next Year | $2.72 | $430.87 |
| P/E Ratio | $62.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.76 | $1.89 |
| 52 Week High | $69.15 | $7.01 |
Technical Indicators
Market Signals| Indicator | CSR | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.35 | 64.04 |
| Support Level | $60.01 | $5.86 |
| Resistance Level | $68.36 | $6.10 |
| Average True Range (ATR) | 1.50 | 0.28 |
| MACD | 0.40 | 0.10 |
| Stochastic Oscillator | 87.50 | 89.37 |
Price Performance
Historical ComparisonAbout CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).